X

Xeris Biopharma Holdings
D

XERS

3.75500
USD
-0.22
(-5.53%)
مغلق
حجم التداول
64,933
الربح لكل سهم
-0
العائد الربحي
-
P/E
-9
حجم السوق
559,800,886
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALDX
    -0.04000
    (-0.59%)
    6.69000 USD
    A
    AQST
    -0.05000
    (-1.63%)
    3.01500 USD
    B
    BHC
    0.13500
    (1.88%)
    7.31000 USD
    E
    EPIX
    -0.02500
    (-1.43%)
    1.72000 USD
    E
    ESPR
    -0.03500
    (-1.88%)
    1.82500 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    I
    INSM
    -2.480
    (-2.97%)
    81.040 USD
    MRK
    MRK
    1.820
    (2.08%)
    89.500 USD
    R
    RDHL
    -0.08000
    (-1.64%)
    4.81000 USD
    S
    SAGE
    0.16000
    (2.24%)
    7.30500 USD
    المزيد
الأخبار
المقالات

العنوان: Xeris Biopharma Holdings

القطاع: Healthcare
الصناعة: Biotechnology
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.